Efficacy results achieved with TYMLOS were MAINTAINED
with sequential therapy1,2

New vertebral fractures: Risk reduction achieved with TYMLOS
was maintained after transitioning to open-label alendronate2

A 25-month analysis* demonstrated 87% RRR in new vertebral fractures with 18 months of TYMLOS→ 6 months of open-label alendronate (fracture incidence 0.6%) vs 18 months of placebo→ 6 months of open-label alendronate (fracture incidence 4.4%) (P<0.0001) and 3.9% ARR2

Percentage of postmenopausal women with osteoporosis with new vertebral fractures at 43 months1*

Percentage of postmenopausal women with osteoporosis with new vertebral fractures graph

TYMLOS or placebo for 18 months, followed by 1 month of no treatment, then up to 24 months of open-label alendronate.3

Results reported in the modified ITT, which included patients who had both pretreatment and posttreatment spine radiographs.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

At least 6x fewer women in the TYMLOS→ open-label alendronate group experienced new vertebral fractures
versus those in the placebo→ open-label alendronate group at 43 months1

See nonvertebral fracture dataMinus iconPlus icon

Nonvertebral fractures: Risk reduction achieved with TYMLOS was maintained after transitioning to open-label alendronate1,2

A 25-month analysis* demonstrated 52% RRR in nonvertebral fractures with 18 months of TYMLOS→ 6 months of open-label alendronate
(fracture incidence 2.7%) versus 18 months of placebo→ 6 months of open-label alendronate (fracture incidence 5.6%) (P=0.017) and 2.9% ARR2

Cumulative incidence of nonvertebral
fractures over 43 months1*

Cumulative incidence of nonvertebral fracture graph

TYMLOS or placebo for 18 months, followed by 1 month of no treatment, then up to 24 months of open-label alendronate; P value based on the log-rank test.2,3

Nonvertebral fractures excluded those of the sternum, patella, toes, fingers, skull, and face, and those associated with high trauma.1

Results reported in the extension study ITT population, which included patients randomized in the efficacy study.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

See change in BMDMinus iconPlus icon

BMD increases achieved with TYMLOS were maintained after transitioning to open-label alendronate1,2

In a 25-month analysis*, significant increases in BMD at the lumbar spine, total hip, and femoral neck achieved with
TYMLOS at 18 months were maintained after transitioning to 6 months of open-label alendronate (P<0.0001 at all sites)2

Patients receiving 18 months of TYMLOS maintained at least a two-fold increase in BMD when followed by 24 months
of open-label alendronate versus those who transitioned from placebo1

Patients receiving 18 months of TYMLOS maintained at least a two-fold increase in BMD when followed by 24 months of open-label alendronate versus those who transitioned from placebo1

Average percentage change from baseline in BMD in postmenopausal women osteoporosis graph

Mean percent change from baseline in BMD in postmenopausal women with osteoporosis at 43 months1*

TYMLOS or placebo for 18 months, followed by 1 month of no treatment, then up to 24 months of open-label alendronate.3

Results reported in ITT population, which included patients enrolled in the extension study; mean percentage change in BMD was LOCF.1

BMD captured with DXA scans.1

The primary and secondary efficacy endpoints for the extension study were at 25 months. The 43-month data are exploratory endpoints.1

Learn more about Together
with Tymlos

offerings and
the savings card

References: 1. Data on file. Radius Health, Inc; Waltham, MA. 2. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018. 3. Cosman F, Miller PD, Williams GC, et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200-210.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.   All rights reserved.    12/18.   TYM-US-02038

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2018 Radius Health, Inc.
All rights reserved. 12/18.
TYM-US-02038

Back to Top